CCR7-dependent stimulation of survival in dendritic cells involves inhibition of GSK3beta

J Immunol. 2009 Nov 15;183(10):6282-95. doi: 10.4049/jimmunol.0804093. Epub 2009 Oct 19.

Abstract

Chemokine receptor CCR7 regulates chemotaxis and survival in mature dendritic cells (DCs). We studied the role of glycogen synthase kinase-3beta (GSK3beta) in the regulation of CCR7-dependent survival. We show that GSK3beta behaves as a proapoptotic regulator in cultured monocyte-derived human DCs and murine splenic DCs in vitro, and in lymph node DCs in vivo. In keeping with its prosurvival role, stimulation of CCR7 induced phosphorylation/inhibition of GSK3beta, which was mediated by the prosurvival regulator Akt1, but it was independent of ERK1/2, a key regulator of chemotaxis. Stimulation of CCR7 also induced translocation of two transcription-factor targets of Akt, prosurvival NF-kappaB and proapoptotic FOXO1, to the nucleus and cytosol, respectively, resulting in DCs with a phenotype more resistant to apoptotic stimuli. We analyzed if GSK3beta was able to modulate the mobilizations of these transcription factors. Using pharmacological inhibitors, small interfering RNA, and a construct encoding constitutively active GSK3beta, we show that active GSK3beta fosters and hampers the translocations to the nucleus of FOXO and NF-kappaB, respectively. Inhibition of GSK3beta resulted in the degradation of the NF-kappaB inhibitor IkappaB, indicating a mechanism whereby GSK3 can control the translocation of NF-kappaB to the nucleus. GSK3beta and FOXO interacted in vivo, suggesting that this transcription factor could be a substrate of GSK3. The results provide a novel mechanism whereby active GSK3beta contributes to regulate apoptosis in DCs. They also suggest that upon stimulation of CCR7, Akt-mediated phosphorylation/inhibition of GSK3beta may be required to allow complete translocations of FOXO and NF-kappaB that confer DCs an extended survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Apoptosis / immunology
  • Cell Survival / drug effects
  • Cell Survival / immunology
  • Chemokine CCL19 / pharmacology
  • Chemokine CCL21 / pharmacology
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Extracellular Signal-Regulated MAP Kinases / immunology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Forkhead Box Protein O1
  • Forkhead Transcription Factors / drug effects
  • Forkhead Transcription Factors / immunology
  • Forkhead Transcription Factors / metabolism
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 / immunology*
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • I-kappa B Kinase / immunology
  • I-kappa B Kinase / metabolism
  • Lithium Chloride / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / immunology
  • NF-kappa B / metabolism
  • Phosphorylation / drug effects
  • Phosphorylation / immunology
  • Proto-Oncogene Proteins c-akt / immunology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, CCR7 / agonists
  • Receptors, CCR7 / immunology*
  • Receptors, CCR7 / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Thiazoles / pharmacology
  • Urea / analogs & derivatives
  • Urea / pharmacology

Substances

  • Adjuvants, Immunologic
  • Chemokine CCL19
  • Chemokine CCL21
  • FOXO1 protein, human
  • Forkhead Box Protein O1
  • Forkhead Transcription Factors
  • NF-kappa B
  • Receptors, CCR7
  • Thiazoles
  • N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea
  • Urea
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Proto-Oncogene Proteins c-akt
  • I-kappa B Kinase
  • Extracellular Signal-Regulated MAP Kinases
  • Glycogen Synthase Kinase 3
  • Lithium Chloride